Zobrazeno 1 - 9 of 9 pro vyhledávání: '"M H, Silverman"'
1
Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults
Autor: M H, Silverman, S, Duggan, G, Bardelli, B, Sadler, C, Key, M, Medlock, L, Reynolds, B, Wallner
Publikováno v: The Journal Of Prevention of Alzheimer's Disease.
Neurodegenerative diseases are devastating conditions that most commonly affect individuals 65 years and older. Currently there are no effective treatments or cures for neurodegenerative diseases, and therapeutics that selectively target the underlyi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68627fb209ffd8444e0da15cd2c685b3
https://doi.org/10.14283/jpad.2022.71
Zobrazit plný text záznamu
2
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men
Autor: P Fishman, A R van Troostenburg, W D H Carey, W D Kerns, I Cohn, E V Clark, K L L Fong, S. Bar-Yehuda, Steven J. Warrington, M H Silverman
Publikováno v: Int. Journal of Clinical Pharmacology and Therapeutics. 42:534-542
Objectives: To assess safety, tolerability, pharmacokinetics and hemodynamic effects of oral CF 101, an A3 adenosine receptor (A3AR) agonist, in healthy men. Methods: One single and 1 repeated dose, parallel-group, ascending dose, double-blind and pl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a78e6556be75c9c2c5cf4a6989c561b6
https://doi.org/10.5414/cpp42534
Zobrazit plný text záznamu
3
Safety, tolerability and pharmacokinetics of subcutaneous Å6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men
Autor: T R Jones, Steven J. Warrington, G.N. Lam, M H Silverman, J A Dyck-Jones, A R van Troostenburg, D Lee
Publikováno v: Int. Journal of Clinical Pharmacology and Therapeutics. 42:253-259
Aims: To assess the safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. Methods: Double-blind, placebo-controlled, parallel-group, dose-rising, phase I study of single
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6925041d996d4a0a8c6f8b947d0b026c
https://doi.org/10.5414/cpp42253
Zobrazit plný text záznamu
4
Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial
Autor: M, David, L, Akerman, M, Ziv, M, Kadurina, D, Gospodinov, F, Pavlotsky, R, Yankova, V, Kouzeva, M, Ramon, M H, Silverman, P, Fishman
Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV. 26(3)
CF101 demonstrated a marked anti-inflammatory effect in Phase 2 studies conducted in patients with rheumatoid arthritis and dry eye syndrome. The aim of this study was to evaluate the safety and efficacy of CF101 for the treatment of patients with mo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::805de9ed8128ebfd0ecd27210155af8f
https://pubmed.ncbi.nlm.nih.gov/21504485
Zobrazit plný text záznamu
5
Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers
Autor: J A Cook, Richard R. Brown, J J Schentag, David E. Nix, M H Silverman, D J Schelling, R M Stroshane
Publikováno v: Antimicrobial Agents and Chemotherapy. 34:974-979
The multiple-dose pharmacokinetics and safety of amifloxacin, a new fluoroquinolone antibacterial agent, were evaluated in healthy male volunteers. Amifloxacin was administered orally at 200, 400, or 600 mg every 12 h (q12h) and 400, 600, or 800 mg e
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ab3f5d2f94c6d5a1ccbd141a66b720a
https://doi.org/10.1128/aac.34.6.974
Zobrazit plný text záznamu
6
Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects
Autor: J A Cook, Richard R. Brown, M H Silverman, A W Boddy, R M Stroshane, R Sauerschell
Publikováno v: Antimicrobial Agents and Chemotherapy. 34:751-754
Amifloxacin pharmacokinetics after a single oral dose in healthy elderly subjects were determined. Five males and five females aged 65 to 79 years and having creatinine clearances of 39.3 to 87.2 ml/h per kg of body weight were given a 200-mg amiflox
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71243e022ddc0eea307b6bbf8e22e88e
https://doi.org/10.1128/aac.34.5.751
Zobrazit plný text záznamu
7
Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group
Autor: M H Silverman, A Iravani, D J Schelling, E J Boyko, R A Wright
Publikováno v: ResearcherID
We conducted a randomized controlled trial of orally administered amifloxacin versus trimethoprimsulfamethoxazole (TMP-SMX) as treatments of acute uncomplicated urinary tract infection in women. Amifloxacin at a dosage of 200 mg twice a day appeared
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5167558b26cf882dfb0cd471d6d669d3
https://doi.org/10.1128/aac.34.4.665
Zobrazit plný text záznamu
9
Polyarteritis nodosa associated with ulcerative colitis
Autor: M H, Silverman
Publikováno v: The Journal of rheumatology. 11(3)
Three months after colectomy for severe ulcerative colitis, an 18-year-old male presented with a multisystem illness characterized by fever, arthralgias, hypertension, and declining renal function. A diagnosis of polyarteritis nodosa was made histolo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::74215197efc50e897be2a0894df17580
https://pubmed.ncbi.nlm.nih.gov/6145799
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje